ZPHC Tirzepatide 50 mg — Weight loss & metabolic control
ZPHC Tirzepatide 50 mg is a dual GIP/GLP-1 receptor agonist (similar to Mounjaro) designed to reduce body weight and improve blood sugar control. It’s administered as a weekly subcutaneous injection.
What it does
Tirzepatide enhances insulin release, suppresses glucagon, reduces your appetite, and increases feelings of fullness — all of which drive weight loss and improve your glucose metabolism and metabolic markers.
How to use it
Getting the best results
Tirzepatide works best when combined with healthy eating and regular exercise. Eat smaller meals and stay well hydrated, especially during the first few weeks when your body is adjusting. You should expect progressive weight loss over the weeks ahead. Gradual dose increases help minimize nausea and other digestive side effects.
Side effects to expect
Common: Nausea, vomiting, diarrhea, constipation, and decreased appetite — most improve as your body adjusts.
Serious (rare): Severe abdominal pain, persistent vomiting, pancreatitis, gallbladder problems, rapid heartbeat, or signs of allergic reaction. Stop use immediately if you experience any of these.
Important safety information
Do not use if you are pregnant or breastfeeding. Use caution if you have a personal or family history of thyroid cancer or MEN2 syndrome. Be aware of potential interactions with other medications and existing health conditions. Stay hydrated to avoid kidney problems from severe vomiting or dehydration.
We recommend using our peptide dosage & reconstitution calculators.

Reviews
There are no reviews yet.